Johnson & Johnson's COVID-19 vaccine, also known as the Janssen vaccine, uses a viral vector approach to deliver genetic instructions to cells in the body to produce a protein found on the surface of the SARS-CoV-2 virus. To develop and test the vaccine, Johnson & Johnson leveraged a range of products from Signosis, including the BMP Responsive Luciferase Reporter HEK293 Stable Cell Line, NFAT Luciferase Reporter Jurkat T Stable Cell Line, as well as the Firefly Luciferase Substrate, Firefly Luciferase Lysis Buffer 5X, and Firefly Luciferase Substrate.
The BMP Responsive Luciferase Reporter HEK293 Stable Cell Line was used to study the response of cells to bone morphogenetic proteins (BMPs), which are involved in bone formation and other cellular processes. The NFAT Lucif
erase Reporter Jurkat T Stable Cell Line was used to study the activity of NFAT, a transcription factor involved in the immune response. The BMP Responsive Luciferase Reporter HEK293 Stable Cell Line was also used to study BMP signaling pathways.
The Firefly Luciferase Substrate, Firefly Luciferase Lysis Buffer 5X, and Firefly Luciferase Substrate were used to measure the activity of luciferase, an enzyme that catalyzes the bioluminescent reaction used to detect gene expression in cells.
By using these products from Signosis, Johnson & Johnson was able to gain insights into cellular processes involved in the immune response and develop a COVID-19 vaccine that contains mRNA.
